RxDoctor Payments Data

Ellen Marie Lucca

Family · Hawley, PANPI 1023652070

Payments from drug & device makers

$5,897in general payments, 2019–2025

Across 296 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$507
  • AstraZeneca$472
  • AbbVie$433
  • Otsuka America Pharmaceutical, Inc.$429
  • Amgen$371
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$5,897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,897 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$83,533
Medicare patients
265
Services billed
1,611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab13$85,744
OzempicSemaglutide36$54,736
MounjaroTirzepatide47$47,141
FarxigaDapagliflozin Propanediol29$35,020
EliquisApixaban40$34,066
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$21,089
XareltoRivaroxaban15$18,153
LinzessLinaclotide14$7,058
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$2,895
Duloxetine Hcl36$2,191
Ursodiol13$1,869
Azelastine Hcl60$1,686
Gabapentin100$1,649
Levothyroxine Sodium148$1,545
Metoprolol Succinate102$1,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,010$54,73636 claims
Lilly USA, LLCMounjaro$507$47,14147 claims
AstraZenecaFarxiga$472$35,02029 claims
PfizerEliquis$153$34,06640 claims
GSKTrelegy Ellipta$296$21,08919 claims
AbbVieLinzess, Synthroid$433$8,11738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Hawley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →